Granulocyte Colony Stimulating Factor


Combined with:

Cyclophosphamide

Indications and Reactions:

Role Indications Reactions
Secondary
Diffuse Large B-cell Lymphoma 15.9%
Bone Marrow Conditioning Regimen 9.8%
Prophylaxis 9.4%
Acute Lymphocytic Leukaemia 9.1%
Haematological Malignancy 8.9%
Product Used For Unknown Indication 7.4%
Prophylaxis Against Graft Versus Host Disease 7.2%
B-cell Lymphoma 6.9%
Acute Myeloid Leukaemia 6.8%
Chronic Lymphocytic Leukaemia 3.9%
Germ Cell Cancer 3.1%
Antibiotic Prophylaxis 1.8%
Antifungal Prophylaxis 1.5%
Allogenic Bone Marrow Transplantation Therapy 1.5%
Burkitt's Lymphoma 1.2%
Lung Metastases 1.2%
Rectal Adenocarcinoma 1.2%
B Precursor Type Acute Leukaemia 1.1%
Non-hodgkin's Lymphoma 1.1%
Osteosarcoma Metastatic 1.1%
Infection 20.2%
Graft Versus Host Disease 10.5%
Thrombocytopenia 8.8%
Febrile Neutropenia 7.0%
Mucosal Inflammation 6.1%
Respiratory Failure 5.3%
Anaemia 3.5%
Lung Infection 3.5%
Pneumonia 3.5%
Pyrexia 3.5%
Sepsis 3.5%
Ventricular Tachycardia 3.5%
Alanine Aminotransferase Increased 2.6%
Atrial Fibrillation 2.6%
Death 2.6%
Diarrhoea 2.6%
Lymphopenia 2.6%
Myelodysplastic Syndrome 2.6%
Pancytopenia 2.6%
Peripheral Sensory Neuropathy 2.6%
Concomitant
Product Used For Unknown Indication 16.2%
Prophylaxis 13.3%
Prophylaxis Against Graft Versus Host Disease 9.2%
Bone Marrow Conditioning Regimen 7.3%
Drug Use For Unknown Indication 6.1%
Aplastic Anaemia 4.9%
Acute Myeloid Leukaemia 4.4%
Diffuse Large B-cell Lymphoma 4.3%
Breast Cancer 4.1%
Haematopoietic Stem Cell Mobilisation 3.8%
Acute Lymphocytic Leukaemia 3.7%
Stem Cell Transplant 3.6%
Infection Prophylaxis 3.2%
Premedication 2.8%
Multiple Myeloma 2.6%
Antifungal Prophylaxis 2.3%
Gastric Cancer 2.1%
Non-hodgkin's Lymphoma 2.1%
Peripheral T-cell Lymphoma Unspecified 2.1%
Chemotherapy 1.9%
Thrombocytopenia 14.2%
Vomiting 9.7%
Pyrexia 6.5%
Off Label Use 5.8%
Cystitis Haemorrhagic 5.2%
Death 5.2%
Neutropenia 5.2%
Sepsis 5.2%
Septic Shock 5.2%
Acute Graft Versus Host Disease 4.5%
Oesophagitis 4.5%
White Blood Cell Count Increased 4.5%
Pneumonia 3.9%
Infection 3.2%
Renal Failure 3.2%
Venoocclusive Liver Disease 3.2%
White Blood Cell Count Decreased 3.2%
Acute Graft Versus Host Disease In Skin 2.6%
Anti-erythrocyte Antibody Positive 2.6%
Chronic Graft Versus Host Disease 2.6%

Drug Data